WHO publishes for the first time a set of dedicated regulatory guidelines for national medicines authorities in low-and middle-income countries (LMICs) to evaluate and set quality standards for oxytocin, an essential maternal health drug used for the prevention and...
Concept Foundation is delighted to report that PT Tunggal, (PTT) Indonesia has been awarded WHO Prequalification of Triclofem®, their intramuscular (IM) depot medroxyprogesterone acetate (DMPA) 150 mg/ml product. This adds a third generic DMPA product to the list...
The use of substandard and counterfeit medicines (SCM) leads to significant health and economic consequences, like treatment failure, rise of antimicrobial resistance, extra expenditures of individuals or households and serious adverse drug reactions including...
A third quality assured, generic DMPA-IM contraceptive product available for procurement
Access to quality magnesium sulfate and implementation of guidelines can help reduce maternal deaths due to preeclampsia. When a mother dies, the impact of her death reaches much further than the individual tragedy. It affects the life and health of the family,...
Appropriate Storage and Management of Oxytocin - a Key Commodity for Maternal Health
Access to Quality Assured generic Intramuscular DMPA continues to rise
Following the highly successful “Incentivising Investments in Quality Medicines” event at the World Health Assembly, USP and partners in the #MedsWeCanTrust Campaign have released a report into the learnings from the event. As a #MedsWeCanTrust partner, we are happy to share the report: The Case for Quality.
Mylan Laboratories Limited has received a risk category 1 ranking from the WHO Expert Review Panel for its generic injectable, medroxyprogesterone acetate depot 150mg/ml.
Fiona Theunissen, MBA and Dr Hans Vemer, CEO of Concept Foundation and former obstetrician, discuss why quality, which is by no means a given, is such an important consideration when purchasing maternal health medicines such as uterotonics.
